PTC Therapeutics (PTCT) Misses Q3 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- BofA Securities Reiterates Buy Rating on Apple (AAPL)
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
PTC Therapeutics (PTCT) Bullish Stance Reiterated at Cowen on Strong Translarna Sales Growth
November 10, 2015 9:34 AM ESTPTC Therapeutics (NASDAQ: PTCT) reported 3Q15 EPS of $(1.27), vs consensus $(1.14). Translarna revenues were $9.8MM, a 59% QoQ growth in sales, vs consensus of $10.4MM.
Investor focus is on if FDA accepts Translarna's rolling NDA (which we think is very likely, target completion... More
